COMPANY

Sigmovir Biosystems, Inc.

HQ: Rockville, MD source · sigmovir.com ↗ · Mid-Atlantic

Location: Rockville, MD · source · Oct 15, 2026

Profile checked Oct 10, 2026

35NIH grants

Timeline

Aug 15, 2025 Grant Government grant — NIH R03: $72,930 (annual award, as published), announced Aug 15, 2025. Agency: NIH/NIAID. Source: government award database. source ↗

Funding

Last 2 years.

Aug 15, 2025 Government grant — NIH R03: $72,930 (annual award, as published), announced Aug 15, 2025. Agency: NIH/NIAID. Source: government award database. source ↗

NIH awards 35

Annual award amounts. Total $15.5M.

2025 NIH contract (government contract; not a grant and not an investment round) 272201700028I-P00004-759302300001-1 FY2025: $282,719 awarded for that fiscal year; activity N01 (OTHER_NIH); PI HAUSCHILD, STEVE; recipient as written: SIGMOVIR BIOSYSTEMS, INC., ROCKV source ↗
Aug 16, 2024 NIH award 3R41HL167254-02S1 FY2024: $62,894 awarded for that fiscal year; activity R41 (STTR); PI BLANCO, JORGE C; recipient as written: SIGMOVIR BIOSYSTEMS, INC., ROCKVILLE, MD. Inducible HMGB1 antagonist for viral- source ↗
Aug 12, 2024 NIH award 5R41HL167254-02 FY2024: $488,080 awarded for that fiscal year; activity R41 (STTR); PI BLANCO, JORGE C; recipient as written: SIGMOVIR BIOSYSTEMS, INC., ROCKVILLE, MD. Inducible HMGB1 antagonist for viral-i source ↗
Jul 31, 2024 NIH award 1R03AI186104-01 FY2024: $72,930 awarded for that fiscal year; activity R03 (OTHER_NIH); PI BLANCO, JORGE C; recipient as written: SIGMOVIR BIOSYSTEMS, INC., ROCKVILLE, MD. RXR/PPARg heterodimer agonists for source ↗
Jun 27, 2024 NIH award 3R41HL167254-01S1 FY2024: $29,640 awarded for that fiscal year; activity R41 (STTR); PI BLANCO, JORGE C; recipient as written: SIGMOVIR BIOSYSTEMS, INC., ROCKVILLE, MD. Inducible HMGB1 antagonist for viral- source ↗
2024 NIH contract (government contract; not a grant and not an investment round) 75N93024C00040-0-9999-1 FY2024: $598,871 awarded for that fiscal year; activity N43 (OTHER_NIH); PI n/a; recipient as written: SIGMOVIR BIOSYSTEMS, INC., ROCKVILLE, MD. REAGENTS FOR IM source ↗
2024 NIH contract (government contract; not a grant and not an investment round) 75N93024D00020-0-759302400002-1 FY2024: $80,435 awarded for that fiscal year; activity N01 (OTHER_NIH); PI BOUKHVALOVA, MARINA; recipient as written: SIGMOVIR BIOSYSTEMS, INC., ROCKVIL source ↗
2024 NIH contract (government contract; not a grant and not an investment round) 75N93024D00020-0-759302400001-1 FY2024: $2,500 awarded for that fiscal year; activity N01 (OTHER_NIH); PI n/a; recipient as written: SIGMOVIR BIOSYSTEMS, INC., ROCKVILLE, MD. Pre-Clini source ↗
2024 NIH contract (government contract; not a grant and not an investment round) 272201700028I-P00002-759302300001-1 FY2024: $407,153 awarded for that fiscal year; activity N01 (OTHER_NIH); PI HAUSCHILD, STEVE; recipient as written: SIGMOVIR BIOSYSTEMS, INC., ROCKV source ↗
Aug 31, 2023 NIH award 1R41HL167254-01 FY2023: $488,080 awarded for that fiscal year; activity R41 (STTR); PI BLANCO, JORGE C; recipient as written: SIGMOVIR BIOSYSTEMS, INC., ROCKVILLE, MD. Inducible HMGB1 antagonist for viral-i source ↗
2023 NIH contract (government contract; not a grant and not an investment round) 272201700028I-0-759302300001-1 FY2023: $836,688 awarded for that fiscal year; activity N01 (OTHER_NIH); PI HAUSCHILD, STEVE; recipient as written: SIGMOVIR BIOSYSTEMS, INC., ROCKVILLE, source ↗
2022 NIH contract (government contract; not a grant and not an investment round) 272201700028I-P00002-759302000001-1 FY2022: $722,205 awarded for that fiscal year; activity N01 (OTHER_NIH); PI HAUSCHILD, STEVE; recipient as written: SIGMOVIR BIOSYSTEMS, INC., ROCKV source ↗
Feb 12, 2021 NIH award 5R44AI109926-06 FY2021: $1,000,000 awarded for that fiscal year; activity R44 (SBIR); PI BLANCO, JORGE C; recipient as written: SIGMOVIR BIOSYSTEMS, INC., ROCKVILLE, MD. Development of VLP vaccine for RSV source ↗
May 21, 2020 NIH award 3R44AI109926-05S1 FY2020: $476,975 awarded for that fiscal year; activity R44 (SBIR); PI BLANCO, JORGE C; recipient as written: SIGMOVIR BIOSYSTEMS, INC., ROCKVILLE, MD. Development of VLP vaccine for RSV source ↗
Mar 4, 2020 NIH award 5R44AI109926-05 FY2020: $1,000,000 awarded for that fiscal year; activity R44 (SBIR); PI BLANCO, JORGE C; recipient as written: SIGMOVIR BIOSYSTEMS, INC., ROCKVILLE, MD. Development of VLP vaccine for RSV source ↗
2020 NIH contract (government contract; not a grant and not an investment round) 272201700028I-0-759302000001-1 FY2020: $984,564 awarded for that fiscal year; activity N01 (OTHER_NIH); PI HAUSCHILD, STEVE; recipient as written: SIGMOVIR BIOSYSTEMS, INC., ROCKVILLE, source ↗
Mar 20, 2019 NIH award 2R44AI109926-04A1 FY2019: $1,000,000 awarded for that fiscal year; activity R44 (SBIR); PI BLANCO, JORGE C; recipient as written: SIGMOVIR BIOSYSTEMS, INC., ROCKVILLE, MD. Development of VLP vaccine for RSV source ↗
2019 NIH contract (government contract; not a grant and not an investment round) 272201700028I-P00002-27200002-1 FY2019: $373,053 awarded for that fiscal year; activity N01 (OTHER_NIH); PI BOUKHVALOVA, MARINA; recipient as written: SIGMOVIR BIOSYSTEMS, INC., ROCKVI source ↗
2018 NIH contract (government contract; not a grant and not an investment round) 272201700028I-0-27200002-1 FY2018: $591,222 awarded for that fiscal year; activity N01 (OTHER_NIH); PI BOUKHVALOVA, MARINA; recipient as written: SIGMOVIR BIOSYSTEMS, INC., ROCKVILLE, source ↗
Jul 15, 2017 NIH award 5R42AI109926-03 FY2017: $933,962 awarded for that fiscal year; activity R42 (STTR); PI BLANCO, JORGE C; recipient as written: SIGMOVIR BIOSYSTEMS, INC., ROCKVILLE, MD. Development of VLP vaccine for RSV source ↗
2017 NIH contract (government contract; not a grant and not an investment round) 272201700028I-0-27200001-1 FY2017: $3,500 awarded for that fiscal year; activity N01 (OTHER_NIH); PI n/a; recipient as written: SIGMOVIR BIOSYSTEMS, INC., ROCKVILLE, MD. ANIMAL MODELS source ↗
Aug 18, 2016 NIH award 2R42AI109926-02 FY2016: $933,962 awarded for that fiscal year; activity R42 (STTR); PI BLANCO, JORGE C; recipient as written: SIGMOVIR BIOSYSTEMS, INC., ROCKVILLE, MD. Development of VLP vaccine for RSV source ↗
Feb 13, 2014 NIH award 1R41AI109926-01 FY2014: $225,000 awarded for that fiscal year; activity R41 (STTR); PI BLANCO, JORGE C; recipient as written: SIGMOVIR BIOSYSTEMS, INC., ROCKVILLE, MD. Development of VPL Vaccine for RSV source ↗
Aug 29, 2013 NIH award 5R43AG043219-02 FY2013: $273,222 awarded for that fiscal year; activity R43 (SBIR); PI BOUKHVALOVA, MARINA S; recipient as written: SIGMOVIR BIOSYSTEMS, INC., ROCKVILLE, MD. The Cotton Rat: Translational Mo source ↗
May 22, 2013 NIH award 5R01AI057575-11 FY2013: $495,638 awarded for that fiscal year; activity R01 (OTHER_NIH); PI BLANCO, JORGE C; recipient as written: SIGMOVIR BIOSYSTEMS, INC., ROCKVILLE, MD. The role of TLR4 and RSV F protei source ↗
Apr 23, 2013 NIH award 5R21AI101480-02 FY2013: $238,284 awarded for that fiscal year; activity R21 (OTHER_NIH); PI BLANCO, JORGE C; recipient as written: SIGMOVIR BIOSYSTEMS, INC., ROCKVILLE, MD. Development of the Cotton Rat Mod source ↗
Jul 26, 2012 NIH award 1R43AG043219-01 FY2012: $273,222 awarded for that fiscal year; activity R43 (SBIR); PI BOUKHVALOVA, MARINA S; recipient as written: SIGMOVIR BIOSYSTEMS, INC., ROCKVILLE, MD. The Cotton Rat: Translational Mo source ↗
Jun 11, 2012 NIH award 1R21AI101480-01 FY2012: $274,807 awarded for that fiscal year; activity R21 (OTHER_NIH); PI BLANCO, JORGE C; recipient as written: SIGMOVIR BIOSYSTEMS, INC., ROCKVILLE, MD. Development of the Cotton Rat Mod source ↗
May 22, 2012 NIH award 5R01AI057575-10 FY2012: $524,620 awarded for that fiscal year; activity R01 (OTHER_NIH); PI BLANCO, JORGE C; recipient as written: SIGMOVIR BIOSYSTEMS, INC., ROCKVILLE, MD. The role of TLR4 and RSV F protei source ↗
Jun 28, 2011 NIH award 5R41AI091246-03 FY2011: $275,045 awarded for that fiscal year; activity R41 (STTR); PI BOUKHVALOVA, MARINA S; recipient as written: SIGMOVIR BIOSYSTEMS, INC., ROCKVILLE, MD. Cotton Rat: Animal Model Predict source ↗